VRDN

Viridian Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality5/10
  • Growth↓ 1/10
  • Momentum↑ 8/10
Viridian Therapeutics sales and earnings growth
VRDN Growth
Low
  • Revenue Y/Y↑ 23340.07%
  • EPS Y/Y↓ -5.50%
  • FCF Y/Y↓ -204.99%
Viridian Therapeutics gross and profit margin trends
VRDN Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -426.60%
  • ROIC↓ -61.20%
Viridian Therapeutics net debt vs free cash flow
VRDN Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -118.9

Viridian Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗